By subscribing to The ASCO Post Electronic Table of Contents (TAP-ETOC), you agree to receive e-mail from us. The purpose of TAP-ETOC is to inform readers about the online publication of an issue of The ASCO Post and share highlights from the new issue. This is a bimonthly e-mail service, with occasional additional e-mails related to supplemental issues of The ASCO Post.
All of the information contained within TAP-ETOC is related to the practice of clinical oncology, including but not limited to recently published research, scientific advancements, therapeutic developments, new drug approvals, professional development news, and announcements from cancer practices, institutions, and societies.
You are free to unsubscribe from TAP-ETOC at any time by following the unsubscribe instructions located at the bottom of each e-mail. Unsubscribes may take up to 10 days to go into effect.
We reserve the right to modify or discontinue TAP-ETOC at any time with or without notice to you and without assigning sufficient cause or reason for doing so. We will not be liable to you or any third party should we exercise this right.
We reserve the right to unsubscribe users of our newsletter service without notice. We will exercise this right with any subscriber whom we believe registered with false data.
Editions of TAP-ETOC may also contain advertising. These banner ads may link to external websites as directed by the advertiser.
Harborside Press publishes TAP-ETOC under a license arrangement with the American Society of Clinical Oncology. The ideas and opinions expressed in The ASCO Post™ do not necessarily reflect those of Harborside Press, LLC, HSP News Service, LLC, or the American Society of Clinical Oncology, Inc. (ASCO®). Follow this link to view the full Disclaimer statement.